<< Back to News

FDA Approves a New Dosing Frequency for  KYPROLIS® (carfilzomib) and dexamethasone

On October 1, 2018 Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to expand the Prescribing Information for KYPROLIS® (carfilzomib) to include a once-weekly dosing option in combination with dexamethasone (once-weekly Kd70) for patients with relapsed or refractory multiple myeloma. 

Click Here to read the entire Press Release

Click Here for more information on Kyprolis